Thelansis

Advanced Gastrointestinal Stromal Tumors (GISTs) Market Outlook Thelansis’s “Advanced Gastrointestinal Stromal Tumors (GISTs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Gastrointestinal Stromal Tumors (GISTs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient shar...

  Advanced Gastrointestinal Stromal Tumors (GISTs) Market Outlook Thelansis’s “Advanced Gastrointestinal Stromal Tumors (GISTs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Gastrointestinal Stromal Tumors (GISTs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Advanced Gastrointestinal Stromal Tumors (GISTs) Overview Gastrointestinal stromal tumors (GISTs) represent 0.1–0.3% of gastrointestinal malignant neoplasms and are primarily located within the mesenchymal tissue of the gastrointestinal tract. These tumors can manifest at any age, with a median patient age of 60–65 years. Clinically, GISTs often present with s...

  Gastrointestinal stromal tumors (GISTs) represent 0.1–0.3% of gastrointestinal malignant neoplasms and are primarily located within the mesenchymal tissue of the gastrointestinal tract. These tumors can manifest at any age, with a median patient age of 60–65 years. Clinically, GISTs often present with symptoms such as gastrointestinal bleeding, anemia, and abdominal pain. The stomach is the most common site of occurrence, accounting for approximately 50–60% of cases, followed by the small intestine (20–30%) and, less frequently, the colon and rectum (5%) and the esophagus (<1%). Metastatic disease is identified in approximately 15% of patients at diagnosis. Before the advent of targeted therapies, the management of GISTs was challenging due to their poor response to conventional chemotherapy and radiation, making surgical resection the primary therapeutic option. However, many patients who initially undergo surgery for GISTs eventually experience disease recurrence. Historic...